Dr. Sunil Verma on Ongoing Treatment Research for HER2-Positive Breast Cancer
Sunil Verma, MD, Medical Director, Tom Baker Cancer Centre, Professor and Department Head, Oncology, Cumming School of Medicine, University of Calgary, discusses the future of immunotherapies and anti-HER2 drugs in the treatment paradigm for HER2-positive breast cancer.
Sunil Verma, MD, Medical Director, Tom Baker Cancer Centre, Professor and Department Head, Oncology, Cumming School of Medicine, University of Calgary, discusses the future of immunotherapies and anti-HER2 drugs in the treatment paradigm for HER2-positive breast cancer. Verma says alongside this future are also novel anti-HER2 agents such as neratinib, which has improved disease free survival in patients with HER2-positive breast cancer, but does come with additional toxicities.
Verma says for patients who do not display a partial complete response, trials are currently ongoing to incorporate trastuzumab into the treatment paradigm.
